The expanding role of TNF-receptor super family member CD40 (tnfrsf5) in autoimmune disease: Focus on Th40 cells

Current Immunology Reviews

Volumn 6, Issue 2, 2010, Pages 130-136

  Vaitaitis, Gisela ^a   Waid, Dan ^a   Wagner Jr , David H ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; CD40; Inflammation; Th40; Tnfr super family

Indexed keywords

CD40 LIGAND; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL COUNT; CELL DEATH; CELL FUNCTION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL;

EID: 77952484742     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339510791111673     Document Type: Article

References (65)

1. Strom L, Laurencikiene J, Miskiniene A, Severinson E. Characterization of CD40-dependent immunoglobulin class switching. Scand J Immunol 1999; 49: 523-32.
2. Rothstein TL. Inducible resistance to Fas-mediated apoptosis in B cells. Cell Res 2000; 10: 245-66.
3. Wagner DH, Jr., Stout RD, Suttles J. Role of the CD40-CD40Ligand interaction in CD4+ T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur J Immunol 1994; 24: 3148-54.
4. Poe J, Wagner Jr. DH, Stout RD, Suttles J. IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis. J Immunol 1997; 159: 846-52.
5. Alderson M R, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178: 669-74.
6. Castle BE, Kishimoto K, Stearns C, Brown ML, Kehry MR. Regulation of expression of the ligand for CD40 on T helper lymphocytes. J Immunol 1993; 151: 1777-88.
7. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-6.
8. Stumpf C, Lehner C, Eskafi S, et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 2003; 5: 629-37.
9. Gong YF, Xiang LX, Shao JZ. CD154-CD40 interactions are essential for thymus-dependent antibody production in zebrafish: insights into the origin of costimulatory pathway in helper T cell-regulated adaptive immunity in early vertebrates. J Immunol 2009; 182: 7749-62.
10. Zheng YB, Gao ZL, Zhong F, et al. Predictive value of serum-soluble CD154 in fulminant hepatic failure. J Int Med Res 2008; 36: 728-33.
11. Chiarelli F, Giannini C, Verrotti A, Mezzetti A, Mohn A. Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria. Diabetes Metab Res Rev 2008; 24: 570-6.
12. Prahalad S, Martins TB, Tebo AE, et al. Elevated serum levels of soluble CD154 in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008; 6: 8.
13. Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest 2006; 116: 769-74.
14. Young RS, Naseem KM, Pasupathy S, Ahilathirunayagam S, Chaparala RP, Homer-Vanniasinkam S. Platelet membrane CD154 and sCD154 in progressive peripheral arterial disease: a pilot study. Atherosclerosis 2007; 190: 452-8.
15. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp30 the ligand for CD40. Science 1993; 281: 1328-30.
16. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004; 37: 457-64.
17. Girvin AM, Dal Canto MC, Miller SD. CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J Autoimmun 2002; 18: 83-94.
18. + Auto-Aggressive T Cells During Insulin-Dependent Diabetes Mellitus. Eur J Immunol 2004; 34: 1488-97.
19. Balasa B, Krahl T, Patstone G, et al. CD40 Ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159: 4620-27.
20. Soong L, Xu JC, Grewal IS, et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 1996; 4: 263-73.
21. Amrani A, Serra P, Yamanouchi J, et al. CD154-dependent priming of diabetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells. Immunity 2002; 16: 719-32.
22. Armitage RJ, Maliszewski CR, Alderson MR, et al. CD40L: a multi-functional ligand. Semin Immunol 1993; 5: 401-12.
23. Aruffo A, Farrington, M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72: 291-300.
24. Waid DM, Vaitaitis GM, Pennock ND, Wagner DH, Jr., Disruption of the homeostatic balance between autoaggressive (CD4+CD40+) and regulatory (CD4+CD25+FoxP3+) T cells promotes diabetes. J Leukoc Biol 2008; 84: 431-9.
25. Vaitaitis GM, Wagner DH, Jr., High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity. PLoS ONE 2008; 3: e2076.
26. Baker RL, Wagner JDH, Haskins KJ. CD40 on NOD CD4 T cells contributes to their activation and pathogenesis. J Autoimmun 2008; 31(4): 385-92.
27. Waid DM, Wagner RJ, Putnam A, et al. A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes. Clin Immunol 2007; 124: 138-48.
28. Murugaiyan G, Agrawal R, Mishra GC, Mitra D, Saha B. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J Immunol 2007; 178: 2047-55.
29. Munroe ME, Bishop GA. A costimulatory function for T cell CD40. J Immunol 2007; 178: 671-82.
30. Grabstein KH, Maliszewski CR, Shanebeck K. The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2. J Immunol 1993; 150: 3141-7.
31. Vaitaitis GM, Poulin M, Sanderson RJ, Haskins KJ, Wagner DH Jr. CD40-Induced Expression of Recombination Activating Gene (RAG) 1 and RAG2: A Mechanism for the Generation of Autoaggressive T Cells in the Periphery. Cutting Edge, J Immunol 2003; 170: 3455-9.
32. Wagner DH, Jr., Vaitaitis G, Sanderson R, Poulin M, Dobbs C, Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc Natl Acad Sci USA 2002; 99: 3782-7.
33. Wagner D H, Jr., Newell E, Sanderson R, Freed JH, Newell MK. Increased expression of CD40 on thymocytes and peripheral T cells in autoimmunity: A mechanism for acquiring changes in the peripheral T cell receptor repertoire. Int J Mol Med 1999; 4: 231-42.
34. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002; 297: 2060-3.
35. Waid DM, Vaitaitis GM, Wagner DH, Jr., Peripheral CD4loCD40+ auto-aggressive T cell expansion during insulin-dependent diabetes mellitus. Eur J Immunol 2004; 34: 1488-97.
36. Serreze DV, Prochazka M, Reifsnyder PC, Bridgett MM, Leiter EH. Use of recombinant congenic and congenic strains of NOD mice to identify a new insulin-dependent diabetes resistance gene. J Exp Med 1994; 180: 1553-8.
37. Haskins K, Portas M, Bergman B, Lafferty K, Bradley B. Pancreatic islet-specific T cell clones from nonobese diabetic mice. Proc Natl Acad Sci USA 1989; 86: 8000-4.
38. Bradley BJ, Wang YY, Lafferty KJ, Haskins K. In vivo activity of an islet-reactive T-cell clone. J Autoimmun 1990; 3: 449-56.
39. Haskins K, McDuffie M. Acceleration of diabetes in yound NOD mice with a CD4+ islet-specific T cell clone. Science 1990; 249: 1433-6.
40. Yellin M, Thienel U. T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2000; 2: 24-31.
41. Garrone P, Neidhardt EM, Garcia E, et al. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995; 182: 1265-73.
42. Desbarats J, Wade T, Wade WF, Newell MK. Dichotomy between naive and memory CD4(+) T cell responses to Fas engagement. Proc Natl Acad Sci USA 1999; 96: 8104-9.
43. Cohen PL, Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9: 243-69.
44. Sobel ES, Katagiri T, Katagiri K, Morris SC, Cohen PL, Eisenberg RA. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 1991; 173: 1441-9.
45. Cohen P L, Eisenberg RA. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunology Today 1992; 13: 427-8.
46. Baker RL, Wagner DH, Jr., Haskins K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun 2008; 31: 385-92.
47. Steinman L. A rush to judgment on Th17. J Exp Med 2008; 205: 1517-22.
48. Yang Y, Weiner J, Liu Y, et al. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J Exp Med 2009. 206: 1549-64.
49. Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009; 119: 61-9.
50. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 2006; 18: 349-56.
51. Suryani S, Sutton I. An interferon-gamma-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J Neuroimmunol 2007; 183: 96-103.
52. Bending D, De La Pena H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009; 119(3): 565-72.
53. McGargill MA, Derbinski JM, Hogquist KA. Receptor editing in developing T cells. Nat Immunol 2000; 1: 336-41.
54. Holman PO, Walsh ER, Hogquist K A. The central tolerance response to male antigen in normal mice is deletion and not receptor editing. J Immunol 2003; 171: 4048-53.
55. Lantelme E, Orlando L, Porcedda P, et al. An in vitro model of T cell receptor revision in mature human CD8+ T cells. Mol Immunol 2008; 45: 328-37.
56. McMahan C, Fink P. Receptor revision in peripheral T cells creates a diverse V beta repertoire. J Immunol 2000; 165: 6902-7.
57. Blish C, Gallay B, Turk G, Kline K, Wheat W, Fink P. Chronic modulation of the TCR repertoire in the lymphoid periphery. J Immunol 1999; 162: 3131-40.
58. McMahan CJ, Fink PJ. RAG reexpression and DNA recombination at T cell receptor loci in peripheral CD4+ T cells. Immunity 1998; 9: 637-47.
59. Zehn D, Bevan MJ, Fink PJ. Cutting edge: TCR revision affects predominantly Foxp3 cells and skews them toward the Th17 lineage. J Immunol 2007; 179: 5653-7.
60. Cooper CJ, Turk GL, Sun M, Farr AG, Fink PJ. Cutting edge: TCR revision occurs in germinal centers. J Immunol 2004; 173: 6532-6.
61. Cooper CJ, Orr MT, McMahan CJ, Fink PJ. T cell receptor revision does not solely target recent thymic emigrants. J Immunol 2003; 171: 226-33.
62. Serra P, Amrani A, Han B, Yamanouchi J, Thiessen SJ, Santamaria P. RAG-dependent peripheral T cell receptor diversification in CD8+ T lymphocytes. Proc Natl Acad Sci USA 2002; 13: 13.
63. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229: 41-66.
64. Chitnis T, Najafian N, Abdallah KA, et al. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001; 107: 575-83.
65. Heath AW, Wu WW, Howard MC. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur J Immunol 1994; 24: 1828-34.